Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders.
Phase of Trial: Phase IV
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Donepezil (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 25 Oct 2016 Results of post-hoc analysis, published in the Journal of Clinical Psychiatry.
- 11 Jul 2014 Status changed to completed as reported by ClinicalTrials.gov record.
- 20 Jul 2011 Results will be presented at the Alzheimer's Association International Conference 2011 (AAIC 2011) according to an Eisai media release. Results were also summarised in the media release.